In 2020, MolDx brought out a groundbreaking new LCD for Pharmacogenetics, which tied coverage to CPIC and FDA recommendations, updating coverage in sync with the updates to those coverage resources. (This summer, 2022, Novitas has offered a draft LCD that would tie or sync its cancer genomic coverage to external resources like NCCN.)
While the body of the LCD focuses on gene:drug pairs endorsed by CPIC and FDA. However, the billing article also has a section called "Multi Drug Panels." These list 5 tests that are covered EITHER for (a) depression, (b) other psych disorders, or (c) both.
The current table of coverage for psych gene panels reads like this:DEX online database (email registration required) and you can look up each test and the price MolDx assigns it. Genesight pegs in at $1568 currently.